相关实验视频
Updated: Feb 18, 2026

06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
1.0K
治疗结果和正在进行的小儿科试验,用于治疗类固醇耐药性性综合征
Chris K Fan1, Heather S Jung1, Yasmine E Pang1
1Division of Pediatric Nephrology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Pediatric nephrology (Berlin, Germany)
|February 16, 2026
概括
新疗法为患有耐固醇脏综合征 (SRNS) 的儿童提供了希望,这种疾病具有高功能衰竭风险. 本综述涵盖了针对儿科SRNS的新型治疗方法和正在进行的临床试验.
科学领域:
- 儿科脏病学 儿科脏病学
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- 儿童类固醇耐药性性综合征 (SRNS) 存在重大挑战,治疗耐药性和进展到衰竭的高率.
- 单一的SRNS形式和对免疫抑制剂的耐药性对儿科患者构成最大的风险.
- 了解SRNS的发病因子对于开发向疗法至关重要.
研究的目的:
- 审查儿科SRNS的队列研究中的当代发现.
- 总结新型治疗剂及其特定的机制性标.
- 介绍儿科SRNS最近和正在进行的临床试验的概述.
主要方法:
- 对当代队列研究的文献综述.
- 对新型治疗剂及其在SRNS中的点进行分析.
- 从最近和正在进行的临床试验中汇编数据.
主要成果:
- 了解SRNS病原学的进步导致了新的向疗法.
- 新型药物解决了与SRNS有关的遗传,免疫和代谢途径.
- 最近和正在进行的八项临床试验正在评估这些新的方法.
结论:
- 尽管面临挑战,但新型疗法对儿科SRNS具有前景.
- 针对性治疗为脏衰竭高风险的儿童提供了新的希望.
- 正在进行的临床试验对于推进儿科SRNS管理至关重要.
相关概念视频
Nephrotic Syndrome II : Assessment and Medical Management
257
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
257
Nephrotic Syndrome III : Nursing Management
358
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
358
Nephrotic Syndrome I : Introduction
705
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
705
Pharmacokinetics in Pediatric Patients: Drug Excretion
284
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
284
Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
538
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
538

